Benzinga | Aug 28, 2020 07:11AM EDT

Guggenheim Initiates Coverage On NeoGenomics with Buy Rating, Announces Price Target of $46

Guggenheim analyst David Westenberg initiates coverage on NeoGenomics (NASDAQ:NEO) with a Buy rating and announces Price Target of $46.